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ABSTRACT | Purpose: To evaluate the effectiveness in 
in traocular pressure reduction and safety of micropulse trans­
scleral diode cyclophotocoagulation in refractory glaucoma. 
Methods: We prospectively evaluated a case series of 21 eyes 
of 21 consecutive patients with refractory glaucoma treated 
with micropulse transscleral diode cyclophotocoagulation 
at 12­month follow­up. The total treatment time was at the 
discretion of the surgeon, considering baseline and target 
intraocular pressure and glaucoma diagnosis. Intraocular 
pressure, inflammation, visual acuity, and number of medi­
cations were monitored. Success was defined as intraocular 
pressure between 6 and 21 mmHg and/or 30% reduction 
from baseline intraocular pressure with or without the use of 
antiglaucoma medications. Visual acuity loss was defined as 
a loss of ≥2 lines of vision on the Snellen chart or a ≥2­level 
decrease in visual function in patients with nonmeasurable 
chart acuity. Results: The mean age was 61.04 ± 12.99 years, 
and 11 (52.4%) patients were male, with most (95%) patients 
showing low visual acuity at baseline (count fingers or worse). 
The mean intraocular pressure was 33.38 ± 15.95 mmHg, and 
the mean number of medications was 3.5 ± 1.1 at baseline. 
After 1, 3, 6, and 12 months, 76.19%, 57.14%, 55.56%, and 
66.67%, respectively, of the patients were classified as treat­
ment successes. Seven (33.3%) patients required new laser 
treatment and were considered treatment failures. The mean 
intraocular pressure reduction was 44.72% ± 29.72% in the 
first week and 41.59% ± 18.93% at the end of follow­up 
(p=0.006). The mean number of medications significantly 
dropped to 2.00 ± 1.7 at the 12­month visit (p=0.044). Com­
plications included hypotony (4.8%), intraocular inflammation 
after 1 month (19%), and visual acuity loss (4.8%). Conclusions: 
Micropulse transscleral diode cyclophotocoagulation was safe 
and effective for reducing intraocular pressure in eyes with 
refractory and advanced glaucoma, with reduced need for 
ocular antihypertensive medication.
Keywords: Glaucoma; Laser therapy; Micropulse transscleral 
diode cyclophotocoagulation; Intraocular pressure; Laser, se mi­
conductor
RESUMO | Objetivo: Avaliar a eficácia na redução da pressão 
intraocular e na segurança da ciclofotocoagulação com laser de 
diodo transescleral em glaucoma refratário. Métodos: Avaliamos 
prospectivamente uma série de casos de 21 olhos de 21 pacien­
tes com glaucoma refratário tratados com ciclofotocoagulação 
com laser de diodo transescleral com acompanhamento por 12 
meses. O tempo total de tratamento ficou a critério do cirurgião, 
considerando a pressão intraocular inicial e alvo e o tipo de 
glaucoma. Pressão intraocular, inflamação, acuidade visual e 
número de medicamentos foram monitorados. O sucesso foi 
definido como pressão intraocular entre 6 e 21 mmHg e/ou 
redução de 30% da pressão intraocular basal com ou sem o uso 
de medicamentos glaucomatosos. Perda da acuidade visual foi 
definida como perda de ≥2 linhas de visão na tabela de Snellen 
ou uma diminuição de ≥ 2 níveis na função visual em pacientes com 
acuidade do gráfico não mensurável. Resultados: A idade média 
foi de 61,04 ± 12,99 anos e 11 (52,4%) pacientes eram do sexo 
masculino, com a maioria (95%) dos pacientes apresentando baixa 
acuidade visual inicialmente (conta dedos ou pior). A pressão intra­
ocular média foi de 33,38 ± 15,95 mmHg, e o número médio de 
medicamentos foi de 3,5 ± 1,1, no início do estudo. Após 1, 3, 6 
e 12 meses, 76,19%, 57,14%, 55,56% e 66,67%, respectivamente, 
dos pacientes foram classificados como sucesso do tratamento. 
Sete (33,3%) pacientes necessitaram de novo tratamento com laser 
e foram considerados falhas no tratamento. A redução média da 
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pressão intraocular foi de 44,72% ± 29,72% na primeira semana e 
41,59% ± 18,93% no final do seguimento (p=0,006). O número 
médio de medicamentos diminuiu significativamente para 2,00 
± 1,7 na visita de 12 meses (p=0,044). As complicações incluíram 
hipotonia (4,8%), inflamação intraocular após 1 mês (19%) e perda 
de acuidade visual (4,8%). Conclusões: A ciclofotocoagulação 
com laser de diodo transescleral foi segura e eficaz para reduzir a 
pressão intraocular em olhos com glaucoma refratário e avançado, 
com necessidade reduzida de hipotensores oculares.
Descritores: Glaucoma; Terapia a laser; Ciclofotocoagulação 
transescleral com laser de diodo micropulsado; Pressão intrao­
cular; Laser semicondutores
INTRODUCTION
Glaucoma is the leading cause of irreversible blindness 
in the world, with approximately 8.4 million people 
blind from glaucoma(1,2). Evidence from long­term clini­
cal trials shows that lowering intraocular pressure (IOP) 
prevents progression at the early and late stages of the 
disease(3­6). Even in the final stages, when visual acuity 
is very low or absent, high IOP is a frequent cause of 
pain and discomfort. Topical medical therapy remains 
the most common initial intervention to lower IOP, but 
some patients do not respond to medical therapy and 
require laser or surgical procedures(7). Several laser or 
surgical procedures are used to treat glaucoma, and 
each has a different safety profile and success rate.
During the past 3 decades, continuous transscleral 
laser diode cyclophotocoagulation (TSCPC) has been an 
alternative to incisional surgery(8). This procedure uses 
an 810­nm wavelength laser that produces a thermal 
effect when absorbed by melanin in the pigmented 
epithelial cells of the ciliary body, which reduces 
aqueous humor production(9). Given the potential risk 
of sight­threatening complications (e.g., phthisis bulbi, 
sympathetic ophthalmia, postoperative inflammation, 
hypotony, and cystoid macular edema) coupled with the 
unpredictability of the IOP­lowering effect, TSCPC has 
been used after clinical treatment or invasive procedu­
res have failed(10­13).
As an alternative to the conventional continuous 
high­intensity energy laser delivery of the TSCPC system, 
micropulse diode laser has been proposed as a safer 
cyclodestructive procedure(14,15). By delivering a series 
of repetitive short pulses of energy separated by rest 
periods, micropulse transscleral cyclophotocoagulation 
(MP­TSCPC) is believed to minimize collateral thermal 
damage to adjacent tissues by allowing nonpigmented 
tissue to remain below the coagulation threshold during 
the off­cycle(15). In the present study, we prospectively 
evaluated the efficacy and safety of MP­TSCP in patients 
with refractory glaucoma who were followed for 12 
months.
METHODS
This prospective interventional study conducted at 
the University of Campinas (UNICAMP), Campinas, São 
Paulo, Brazil, was approved by the Ethics Committee of 
the University of Campinas. The protocol was in com­
pliance with Good Clinical Practices and the tenets of 
the Declaration of Helsinki (1996).
Patients
Twenty­one eyes of 21 consecutive patients with 
refractory glaucoma, defined as medically uncontrolled 
glaucoma despite previous glaucoma surgery, who were 
seen at the outpatient clinic of UNICAMP were enrolled 
and followed for 12 months. The eyes had no previous 
ciliary ablative surgery, and the patients were either 
poor candidates for additional filtering surgery or had 
declined an additional incisional procedure. Patients 
with no light perception but who presented with ocu­
lar pain associated with high IOPs were also enrolled. 
Patients with ongoing ocular inflammation or infection 
were excluded.
Examination
Before the intervention, all participants underwent 
a comprehensive ophthalmological examination, which 
included review of medical history, best­corrected visual 
acuity (BCVA), slit­lamp biomicroscopy, IOP measure­
ment using Goldmann applanation tonometry, dilated 
fundoscopy examination, and standard automated pe­
rimetry using the Humphrey Field Analyzer (Carl Zeiss 
Meditec, Dublin, CA) whenever the visual acuity allowed. 
Spectral­domain optical coherence tomography (OCT) 
imaging of the macula with Cirrus HD­OCT (Carl Zeiss 
Meditec, Inc., Dublin, CA, USA) was performed in eyes 
without media opacities.
Intervention
MP­TSCPC was performed by using the Cyclo G6 
Glaucoma Laser System and a MicroPulse P3 probe (Iri­
dex, Mountain View, CA, USA) by 1 of 2 surgeons (V.P.C. 
and J.P.C.V.). Following peribulbar anesthesia, the probe 
was applied firmly to the conjunctiva and moved in a 
continuous sliding arc motion (“painting”) avoiding the 3 
and 9 o’clock positions. In contrast to the G­probe used 
for TSCPC, the MicroPulse P3 probe targets the pars 
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plana instead of the pars plicata and places the quartz 
optical fiber 3 mm posterior to the limbus. The device 
was set on micropulse mode with 2000 mW of 810 nm 
infrared diode laser radiation, with a 0.5 ms on­time and 
a 1.1 ms off­time and an equivalent duty factor of 31.3% 
(Figure 1). The total treatment time was at the discretion 
of the surgeon who considered baseline and target IOPs 
and glaucoma diagnosis, i.e., higher baseline IOPs and 
lower target IOPs received longer treatment. We pres­
cribed postoperative steroid eye drops (prednisolone 
acetate, 1% q.i.d.) for 3 weeks after the procedure.
Follow-up
Patients were seen on days 1, 7, and 30 and months 
3, 6, and 12 after the procedure. The follow­up exami­
nation included determining BCVA, slit­lamp biomicros­
copy, dilated fundoscopy, and OCT imaging. IOP was 
measured twice by using a Goldmann applanation to­
nometer, and the mean was calculated. Additional visits 
were scheduled as needed. The number of antiglaucoma 
medications and clinical complications was annotated. 
Hypotony was defined as an IOP <6 mmHg at 2 con­
secutive visits, and prolonged intraocular inflammation 
was defined as an anterior chamber inflammation(16) 
(1+ cells or more) presented for at least 1 month after 
treatment. Visual acuity loss was defined as a loss of 
≥2 lines of vision on the Snellen chart or a ≥1­level 
decrea se in visual function (e.g., from count fingers to 
hand movements).
Outcome measures
Success was defined as an IOP between 6 and 21 mmHg 
and/or a minimum of 30% IOP reduction from baseline, 
with or without glaucoma medication, after a single 
MP­TSCPC application. For patients with an IOP 
<21 mmHg at enrollment, an IOP reduction >30% from 
the baseline was required for treatment success. The 
need for a new surgical intervention (including a new 
MP­TSCPC) for IOP control at any time during follow­up 
was also considered to be a failure. We also evaluated 
the number of antiglaucoma medications and the fre­
quency of postoperative complications.
Statistical analysis
The values were characterized by the mean and stan­
dard deviation, median, and minimum and maximum 
values. For the purposes of the Kaplan­Meier plots, 
the date of treatment failure was defined as the first 
post­laser visit when a success­defining IOP level was 
not achieved.
All analyses were performed in the open­source envi­
ronment R (R Foundation, Vienna, Austria) and by using 
the commercially available software, Stata version 15 
(StataCorp LP, College Station, Texas, USA). The alpha 
level (type I error) was set at 0.05.
RESULTS
Twenty­one eyes of 21 consecutive patients underwent 
MP­TSCPC application. Two (9.5%) patients did not 
participate in the 1­year follow­up visit. One of the pa­
tients died between the 6th and 12th month after surgery 
from causes unrelated to the procedure. The mean age 
was 61.04 ± 12.99 years, and 11 (52.4%) patients were 
male. The vast majority (95%) of patients had BCVA 
below measurable values in the Snellen visual acuity 
chart (count fingers or worse), and 7 (33%) had no light 
perception at baseline. Among the 21 patients, 4.8% had 
traumatic, 9.5% had silicone oil­induced, 33.3% had pri­
mary open­angle, and 52% had neovascular glaucoma. 
Demographics and clinical characteristics are summari­
zed in table 1.
The mean IOP was 33.38 ± 15.95 mmHg at baseline. 
Success rates were 71.43%, 76.19%, 57.14%, 55.56%, 
and 66.67% at day 7 and 1, 3, 6, and 12 months, res­
pectively, after 1 single MP­TSCPC treatment (mean 
mW= milliwatts; ms= milliseconds.
Figure 1. Standard versus micropulse energy delivery configuration. In 
continuous TSCPC, the pulse length indicates the amount of time (ms) the 
laser delivers the indicated power (mW), either in single-shot or repeat 
mode. For MP-TSCPC, the treatment time corresponds to the total time 
length in which ≥1 smaller pulses may be fired. In this study, the device 
was set to 2000 mW of 810 nm infrared diode laser radiation, with a 0.5 ms 
on-time and a 1.1 ms off-time (duty factor of 31.3%). The total time was at 
the discretion of the surgeon. 
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treatment time of 183.3 ± 72.1 s). The 2 subjects 
with refractory glaucoma enrolled with a baseline IOP 
<21 mmHg (16 and 19 mmHg) achieved the required 
IOP reduction of >30% to be considered a treatment 
success by month 3. The average IOP reduction was 
44.72% ± 29.72% in the first week and 41.59% ± 
18.93% at the end of follow­up (Figure 2).
Seven (33.3%) patients required a new laser treatment 
and were considered to be treatment failures: 3 patients 
underwent continuous TSCPC 2 months after MP­TSCPC 
and 1 after 3 months, all of them because of uncontrolled 
IOP under maximum medical therapy. The other 3 pa­
Table 1. Demographics and clinical characteristics of the study patients
Age (years)* 61.04 ± 12.99









Silicon oil­induced 2 (9.52%)
POAG 7 (33.3%)
Neovascular 11 (52.4%)
*Mean and standard deviation. 
BCVA= best­corrected visual acuity; CF= count fingers; HM= hand movement; 
LP= light perception; NLP= no light perception; POAG= primary open­angle glaucoma.
PO= postoperative day.
Figure 2. (A) Mean intraocular pressure (IOP) and (B) mean 
IOP reduction over time.
A
B Figure 4. Kaplan-Meier cumulative survival analysis curve 
for (A) all diagnosis and (B) comparative curves between 
neovascular glaucoma and other glaucoma diagnosis. 




Figure 3. Mean number of antiglaucoma medications over time. 
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tients, who were NLP and had a painful eye at baseline, 
presented with high IOPs and no ocular pain after 6 
months but refused any further laser treatment.
Figure 3 shows the mean number of antiglaucoma 
medications over time. At enrollment, the patients used 
an average of 3.48 drugs. This number significantly de­
creased to 1.90 in the first month and slightly increased 
toward the end of follow­up (2.00 ocular medications at 
the 12­month visit; p=0.044).
Figure 4 illustrates the Kaplan­Meier survival curve 
after MP­TSCPC treatment. At 12 months, the success 
rate was 66.67%. Survival rates between neovascular 
glaucoma patients and other glaucoma diagnosis were 
not significantly different (p=0.821).
One patient with neovascular glaucoma (NVG) sho­
wed 0 mmHg IOP on postoperative day 30 and was 
treated with atropine 1% and prednisolone 1% eye drops 
for 1 month, later presenting with IOPs between 9 and 
Table 2. Review of the current literature
Authors Study type Sample Laser settings Follow-up* Baseline IOP* Final IOP*
Number. of 
medications* Outcome/success Complications
Tan et al, 
2010(15)
Prospective 40 eyes of 38 
patients
2000 mW for 
100 s 
17.3 ± 2.0 
months
40.1 ± 11.6 24.6 ± 9.6 mmHg 2.1 ± 1.1 to
1.3 ±1.0
IOP < 21 mmHg or 
> 30% reduction 
with or without 
medications
Success rate: 80% 
(32 out of 40 eyes) 
at 18 months
4 eyes (10%): persistent 
inflammation for 4 weeks 
7 eyes (17.5%): hyphema 
post laser (neovascular 
glaucoma) No cases 









14 eyes  
(MP­TSCPC 
group) 14 eyes 
(TSCPC group)
2000 mW for 
100 s
17.5 ± 1.6 
months
36.5 mmHg (29.5, 
56.5) median (IQR)
20.0 mmHg (16.0, 
23.5) median (25th, 
75th percentile)
2 (1.75, 3.00) to 
1 (1, 2) median 
(25th, 75th 
percentile)
IOP 6­21 mmHg 





Success rate: 52% at 
12 months; 75% at 
18 months
1 eye (4%): vision loss 
from hands motion to no 
light perception 




No cases of hypotony
Kuchar et 
al, 2016(25)
Retrospective 19 patients 2000 mW for 
100­240 s.
60.3 days 37.9 mmHg 22.7 mmHg 2.6 to 1.9 IOP < 21 mmHg or 
> 20% reduction 
with or without 
medications 
Success rate: 73.7% 
(14 eyes); 89.5% 
(17 eyes) with 
retreatment
1 eye (5%): hypotony
4 eyes (20%): lost one 
line of vision
4 eyes (20%): gained one 
line of vision
No cases of prolonged 
inflammation or phthisis 
bulbi
Lee et al, 
2017(24)
Retrospective 27 eyes (25 
adult patients) 
9 eyes (9 
pediatric 
patients)
2000 mW for 
320 s 
12 months 28.41 ± 8.32 mmHg 
(adult patients) 
34.28 ± 9.92 mmHg 
(pediatric patients)
18.98 ± 6.45 mmHg 
(adult patients), 
27.20 ± 15.68 mmHg 
(pediatric patients)
Not disclosed IOP < 21 mmHg or 
> 20% reduction 










No shallow chamber, 
choroidal effusion, 




Retrospective 84 eyes 2000 ­ 1900 mW 
for 319 s (mean)
4.3 ± 3.0 months 27.7 ± 10.3 mmHg 14.6 ± 8.8 mmHg at 
3 months
11.1 ± 4.4 at 12 
months
3.3 ± 1.0 to
2.3 ± 1.5
Not set 8 and 3 eyes: persistent 




41%: vision loss of at
least 1 line
No cases of phthisis 




Retrospective 79 eyes of 79 
patients
2000 mW for 300 s 
(mean)






Success rate: 75% at 
3 months, 66% at 6 
months, and 67% at 
last follow­up
7 eyes (8.8%): hypotony
21 eyes (26%): prolonged 
inflammation for 
>3months
13 eyes (17%): visual loss 
of ≥2 lines
4 eyes (5%): 
macular edema




*Mean ± standard deviation, unless otherwise noted; mW= milliwatts; s= seconds; mmHg= millimeters of mercury; IOP= intraocular pressure; MP­TSCPC= micropulse transscleral 
cyclophotocoagulation; TSCPC= transscleral cyclophotocoagulation.
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10 mmHg until the end of follow­up. This patient had 
the highest IOP at baseline (78 mmHg) and received the 
longest exposure to MP­TSCPC (160 s per 180o).
Four (19%) patients presented with intraocular in­
flammation at the 1­month visit after MP­TSCPC, and 
1 (4.7%) patient presented at the 3­month visit. Although 
characterizing visual loss in patients with very low vision 
is unreliable, this complication was observed in 1 pa­
tient at the 3­month visit (from hand movement to light 
perception). Patients considered as failures completed 
scheduled visits up to 1 year to assess possible late com­
plications. No patient showed signs of phthisis bulbi, or 
macular edema in OCT.
DISCUSSION
In this study, MP­TSCPC effectively lowered IOP in 
patients with refractory glaucoma, with relatively few 
complications. The mean IOP was significantly reduced 
from the first week of treatment (44.7% reduction) and 
consistently maintained its effectiveness up to 1 year 
(41.6% reduction).
TSCPC has been used for decades as a noninvasive 
treatment for patients who are not good surgical can­
didates or with poor visual potential, with reported 
success rates in the range of 34% to 94%(10), but with a 
number of known complications. The severity of these 
complications is secondary to the collateral damage to 
surrounding tissues, including the nonpigmented epi­
thelium, ciliary body stroma, and ciliary muscles(17). By 
delivering energy in an intermittent fashion, MP­TSCPC 
is believed to spare those structures from significant da­
mage by gradually building up a photocoagulative state 
mainly in the pigmented epithelium(18).
Micropulse diode laser has been successfully used in 
the management of retinal disorders, including macular 
edema secondary to diabetic retinopathy and branch reti­
nal vein occlusion(19­21). In retinal pigment epithelium mo­
dels, Li and colleagues demonstrated that the mi cropulse­
delivered energy partially suppressed anti­inflammatory 
mediators, which slowed normal cellular stress response 
and compensatory healing mechanisms and allowed 
faster protein denaturation(22). This offers a possible rea­
son as to why micropulse can cause biological stress or 
even induce apoptosis without evident necrosis in the 
ciliary body(23).
Data on clinical studies with micropulse diode laser 
in glaucoma, however, are limited (Table 2). To the best 
of our knowledge, only 2 other studies, which were pu­
blished by the same group of investigators, have evalua­
ted MP­TSCPC outcomes prospectively. In the first study 
of its kind, Tan et al.(15) followed 40 eyes of 38 patients 
for an average of 17.3 ± 2.0 months and observed a 
mean IOP reduction from 40.1 ± 11.6 mmHg to 24.6 ± 
9.9 mmHg, which resulted in an 80% success rate (IOP 
between 6 and 21 mmHg and/or 30% reduction from 
baseline with or without medication) after MP­TSCPC. 
Aquino et al.(14) observed a similar success rate in the 
MP­TSCPC group (75% at 18 months by the same crite­
ria) in a prospective randomized study that compared 
micropulse and standard TSCPC, with higher success 
rates for MP­TSCPC. It should be noted, however, that 
in both studies, the need for a repeat laser procedure 
was not considered to be a failure, with 30% of eyes 
requiring a second treatment and 17% requiring a third 
treatment with MP­TSCPC(14). Our series shows a suc­
cess rate of 66.67% at 1 year when applying the same 
success criteria after a single laser procedure. Unlike the 
previously cited studies, our methodology allowed the 
surgeon to deliver different treatment times (i.e., longer 
treatments for worse cases) with a mean treatment time 
of 183.3 ± 72.1 s, which is higher than the fixed time of 
100 s in these studies. We believe that an individualized 
treatment plan provides better IOP outcomes, although 
no standard algorithm has been proposed, and we relied 
on the surgeon’s expertise and gestalt.
Retrospective studies have also reported IOP lowe­
ring with variable success rates ranging from 22.2% in 
pediatric patients to 72.2% in adults at the end of the 
first postoperative year(24) or 73.7%(25) to 75%(26) after 
shorter follow­ups of 60.3 and 90 days, respectively. 
Nonetheless, these studies are diverse in methodology 
and limited in follow­up time.
The reduction in the number of required antiglaucoma 
medications after MP­TSCPC is remarkable. Previous 
studies have reported a significant decrease in this 
number, ranging from 2.1­3.3 at baseline to 1.3­2.3 me­
dications at the last follow­up on average(14,15,18,25). Simi­
larly, we observed a notable drop in the number of ocular 
glaucoma medications from the first month onwards 
(Figure 2), although the number oscillated over time as 
treatment was adjusted after each visit according to drug 
tolerability and target IOP.
Complications
When new technologies are introduced, thorough 
follow­up and careful enrollment are necessary to inves­
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tigate potential complications. Concerning the nature 
of this procedure and the complications of continuous 
TSCPC, we elected to include eyes with low visual acui­
ties and refractory glaucomas in this initial study. Hence, 
95% of our patients showed visual acuities of <20/400 
at baseline. However, in 1 patient with neovascular glau­
coma, we observed consistent visual acuity loss (from 
hand movements to light perception). Nonetheless, it 
is questionable if the visual acuity loss in this case was 
secondary to the laser procedure or a consequence of 
the natural history of the disease. Emanuel et al.(18) pu­
blished the largest cohort of patients to date who had 
undergone MP­TSCPC and observed that a substantial 
proportion (41%) of patients experienced loss of ≥1 line 
of vision after MP­TSCPC, including 3 patients who lost 
light perception. However, the mean follow­up was 
short (4.3 ± 3.0 months), with most patients monitored 
for ≤1 month. This same group later reported high rates 
of visual loss in a longer follow­up of 7.8 ± 4.5 months 
in which 13 (17%) eyes from a different series of patients 
lost ≥2 lines of vision(26). A lower incidence of visual 
loss was observed by Aquino et al.(14) (1 patient in the 
MP­TSCPC group, from hand motion to no light per­
ception), although improvement of 1 line of vision was 
observed by Tan et al.(15) in 4 (10%) patients. Kuchar et 
al.(25) reported that 20% of patients lost ≥1 line of vision, 
whereas another 20% gained 1 line of vision after a short 
mean follow­up of 60.3 days. It is important to note that 
all previous studies also enrolled mostly patients with 
low vision (no light perception to 20/200).
Only 1 patient showed hypotony in our study, but 
it was transitory and successfully treated with topical 
steroids and atropine. Hypotony was the most common 
complication observed by Emanuel et al.(18), with 8 and 
3 eyes showing persistent hypotony at 3 and 6 months, 
respectively. In their study, laser settings and time of 
treatment were determined by the treating physician. 
In fact, the mean treatment time reported by these authors 
was 319 s, which was notably higher than ours. Similarly, 
Williams et al.(26) described a broader range of complica­
tions than that previously reported for MP­TSCPC, which 
is possibly related to longer treatment times (mean 
treatment time of 300 s). Conversely, our patient with 
persistent hypotony was also treated for a longer time 
(320 s) because of very high baseline IOP (78 mmHg) 
caused by neovascular glaucoma. No cases of hypotony 
were observed by Tan et al.(15) and Aquino et al.(14) at a 
fixed total treatment time of 100 s. Although no data is 
available for MP­TSCPC, an increased risk of complica­
tions is associated with higher energies in continuous 
TSCPC(27).
Postoperative intraocular inflammation was common 
following MP­TSCPC. Four (19%) patients in our study 
required extended treatment with prednisolone 1%, 
which resolved after 1 month. All of them had neovas­
cular glaucoma and were treated for an average of 205 s 
(range, 160­240 s). Emanuel et al.(18) observed that 74% 
(45/61 eyes) were on topical steroids at postoperative 
month 3 because of some degree of anterior chamber 
cell and/or flare. Lee et al.(24) reported a 65% prevalence 
of mild postoperative inflammation for 2 to 4 weeks 
postoperatively in 27 eyes in a sample that included 9 
pediatric patients. Williams and colleagues(26) found an 
association of non­white race with prolonged inflam­
mation after MP­TSCPC (OR, 3.61; 95% CI, 1.27­10.23; 
p=0.02). In prospective studies, the prevalence of pro­
longed intraocular inflammation has been found to be 
lower (4%­10%)(14,15). This apparent discrepancy is be­
cause of a lack of standardization both in the definition 
and treatment of persistent inflammation.
We followed a small subgroup (14%) of patients 
without media opacities with macular OCT scans, and 
none of those eyes presented with macular edema. Four 
(5%) patients were clinically diagnosed as having macu­
lar edema by Williams et al.(26). Other studies did not 
report this complication. Similar to the present study, 
no cases of sympathetic ophthalmia, scleral perforation, 
or endophthalmitis were observed by previous authors.
However, 2 cases of phthisis bulbi were recently 
described(26) in patients with complex ocular histories 
(1 with nanophthalmos and 1 with neovascular glau­
coma and uncontrolled diabetes). Yet, most evidence 
to date suggests that MP­TSCPC is an effective and safe 
alternative to traditional continuous TSCPC, with possi­
ble decreased rates of complications(14,15,18,24­26).
Limitations
This study had several limitations. The low baseline 
visual acuity of our patients precluded the investigation 
of the safety of this procedure in eyes with good visual 
function. In TSCPC, the risk of complications is affected 
by the type of glaucoma, with NVG patients having a 
significantly increased risk of complications and fai­
lure(27,28). Tan et al.(15) also reported a higher failure rate 
in patients with NVG (6/12 eyes). There was no signifi­
cant statistical difference in the cumulative survival rates 
between NVG and the other types of glaucoma (p=0.825). 
New studies, including logistic regression analysis, to 
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accurately identify predictors of failure with larger sam­
ple sizes should be conducted to allow better compari­
sons. Although no patient spontaneously reported ocu­
lar pain during laser treatment or during follow­up visits, 
we did not use a scale of pain or discomfort in our series. 
It has been previously observed that 94.7%­95.0% of the 
patients who underwent MP­TSCPC reported mild to no 
pain according to a verbal analog pain scale (14,15). Finally, 
longer follow­up is desirable to establish efficacy and 
long­term complications.
We demonstrated that MP­TSCPC is a safe surgical 
option for eyes with refractory and advanced glaucoma, 
with a reduced need for antiglaucoma medications after 
1 year. Further studies with longer follow­up, including 
in eyes with early to moderate disease and better base­
line visual acuities, are needed to better determine the 
indications and safety of this procedure.
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